CN116731180A - 抗ror1抗体及其制备和使用方法 - Google Patents

抗ror1抗体及其制备和使用方法 Download PDF

Info

Publication number
CN116731180A
CN116731180A CN202310854068.5A CN202310854068A CN116731180A CN 116731180 A CN116731180 A CN 116731180A CN 202310854068 A CN202310854068 A CN 202310854068A CN 116731180 A CN116731180 A CN 116731180A
Authority
CN
China
Prior art keywords
seq
antigen
antibody
binding fragment
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310854068.5A
Other languages
English (en)
Chinese (zh)
Inventor
欧勒·奥尔森
菲尔·谭
夏冬
戴维·耶利曼
布莱恩·科瓦切维奇
比尔·布雷迪
布莱尔·伦肖
高泽人
朱义
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chengdu Bailidote Biological Pharmaceutical Co ltd
Original Assignee
Chengdu Bailidote Biological Pharmaceutical Co ltd
Seattle Immunization Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Bailidote Biological Pharmaceutical Co ltd, Seattle Immunization Co filed Critical Chengdu Bailidote Biological Pharmaceutical Co ltd
Publication of CN116731180A publication Critical patent/CN116731180A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202310854068.5A 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法 Pending CN116731180A (zh)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201762524554P 2017-06-25 2017-06-25
US201762524557P 2017-06-25 2017-06-25
US201762524558P 2017-06-25 2017-06-25
US62/524,558 2017-06-25
US62/524,557 2017-06-25
US62/524,554 2017-06-25
US201762545603P 2017-08-15 2017-08-15
US62/545,603 2017-08-15
US201762551065P 2017-08-28 2017-08-28
US201762551035P 2017-08-28 2017-08-28
US201762551032P 2017-08-28 2017-08-28
US62/551,032 2017-08-28
US62/551,065 2017-08-28
US62/551,035 2017-08-28
CN201880038332.5A CN110869389B (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法
PCT/US2018/039152 WO2019005636A2 (en) 2017-06-25 2018-06-22 ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880038332.5A Division CN110869389B (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法

Publications (1)

Publication Number Publication Date
CN116731180A true CN116731180A (zh) 2023-09-12

Family

ID=64742585

Family Applications (7)

Application Number Title Priority Date Filing Date
CN202310854068.5A Pending CN116731180A (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法
CN202310854013.4A Pending CN116731179A (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法
CN201880038332.5A Active CN110869389B (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法
CN202310929014.0A Pending CN116769035A (zh) 2017-06-25 2018-06-22 抗4-1bb抗体及其制备和使用方法
CN201880038385.7A Active CN110799539B (zh) 2017-06-25 2018-06-22 抗4-1bb抗体及其制备和使用方法
CN202310854150.8A Pending CN116925227A (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法
CN202310929184.9A Pending CN116789832A (zh) 2017-06-25 2018-06-22 抗4-1bb抗体及其制备和使用方法

Family Applications After (6)

Application Number Title Priority Date Filing Date
CN202310854013.4A Pending CN116731179A (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法
CN201880038332.5A Active CN110869389B (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法
CN202310929014.0A Pending CN116769035A (zh) 2017-06-25 2018-06-22 抗4-1bb抗体及其制备和使用方法
CN201880038385.7A Active CN110799539B (zh) 2017-06-25 2018-06-22 抗4-1bb抗体及其制备和使用方法
CN202310854150.8A Pending CN116925227A (zh) 2017-06-25 2018-06-22 抗ror1抗体及其制备和使用方法
CN202310929184.9A Pending CN116789832A (zh) 2017-06-25 2018-06-22 抗4-1bb抗体及其制备和使用方法

Country Status (5)

Country Link
US (2) US11987635B2 (enExample)
EP (2) EP3645741A4 (enExample)
JP (3) JP7222987B2 (enExample)
CN (7) CN116731180A (enExample)
WO (2) WO2019005638A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
KR20220140534A (ko) * 2020-01-30 2022-10-18 온크터널 테라퓨틱스 인코포레이티드 암 치료를 위한 egfr 억제제와 ror1 억제제의 조합
KR20220148209A (ko) * 2020-02-28 2022-11-04 상하이 헨리우스 바이오테크, 인크. 항cd137 작제물 및 그 용도
CN111499746B (zh) * 2020-04-28 2020-11-24 优睿赛思(武汉)生物科技有限公司 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用
US20230235055A1 (en) * 2020-07-28 2023-07-27 The Board Of Regents Of The University Of Texas System Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
TWI818308B (zh) * 2020-09-03 2023-10-11 大陸商和鉑醫藥（上海）有限責任公司 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
US12545716B2 (en) 2021-07-19 2026-02-10 Immunome, Inc. Immunoconjugates and methods
WO2023077026A1 (en) 2021-10-28 2023-05-04 Lyell Immunopharma, Inc. Methods for culturing cells expressing ror1-binding protein
CN116333139B (zh) * 2021-12-22 2026-02-27 上海复旦张江生物医药股份有限公司 一种抗fda0128抗体、其制备方法和应用
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
CN118745226B (zh) * 2023-06-07 2026-02-17 浙江博锐生物制药有限公司 抗ror1抗体及其应用
CN117467004B (zh) * 2023-10-09 2024-06-21 武汉爱博泰克生物科技有限公司 抗人钙网膜蛋白的兔单克隆抗体及其应用
WO2025106600A2 (en) * 2023-11-15 2025-05-22 Systimmune, Inc. Anti-dll3 antibody and method of making and using thereof
CN117624355B (zh) * 2023-11-30 2024-05-14 无锡傲锐东源生物科技有限公司 一种抗人乙酰化tau274兔单克隆抗体及其应用
CN117736330B (zh) * 2024-01-24 2024-05-17 上海沙砾生物科技有限公司 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
CN118930648B (zh) * 2024-08-22 2025-02-28 武汉爱博泰克生物科技有限公司 抗人pax8蛋白的兔单克隆抗体、抗体偶联物及其应用
CN121851161B (zh) * 2026-03-16 2026-05-08 南京诺唯赞医疗科技有限公司 α-syn特异性抗体及其在帕金森辅助诊断试剂盒中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273073A1 (en) * 2011-01-14 2013-10-17 The Regents Of The University Of California Therapeutic Antibodies against ROR-1 Protein and Methods for Use of Same
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途
US20150232569A1 (en) * 2012-08-24 2015-08-20 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE60232895D1 (de) * 2001-10-09 2009-08-20 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
WO2006029220A2 (en) * 2004-09-08 2006-03-16 Ohio State University Research Foundation Combination therapy with anti-ctla4 and anti-4-1bb antibodies
AU2015252014B2 (en) * 2009-04-23 2017-03-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
SG10201912092VA (en) * 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
CA2818992C (en) * 2010-12-01 2021-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CA2935748A1 (en) * 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
DK3237005T3 (en) * 2014-12-22 2024-11-18 Systimmune Inc Bispecific tetravalent antibodies and methods of making and using thereof
CN104817642B (zh) * 2015-05-04 2018-03-27 北京百普赛斯生物科技有限公司 抗人ror1单克隆抗体及其制备方法与应用
JP2021519289A (ja) * 2018-03-27 2021-08-10 システィミューン， インク．Ｓｙｓｔｉｍｍｕｎｅ， Ｉｎｃ． ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273073A1 (en) * 2011-01-14 2013-10-17 The Regents Of The University Of California Therapeutic Antibodies against ROR-1 Protein and Methods for Use of Same
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途
US20150232569A1 (en) * 2012-08-24 2015-08-20 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Also Published As

Publication number Publication date
CN110799539B (zh) 2023-08-15
WO2019005638A2 (en) 2019-01-03
JP7222987B2 (ja) 2023-02-15
CN110869389B (zh) 2023-07-28
EP3645742A4 (en) 2021-07-14
WO2019005636A2 (en) 2019-01-03
JP7464764B2 (ja) 2024-04-09
US20210277109A1 (en) 2021-09-09
CN110869389A (zh) 2020-03-06
CN110799539A (zh) 2020-02-14
EP3645741A4 (en) 2021-08-25
JP2020531043A (ja) 2020-11-05
US20210188989A1 (en) 2021-06-24
CN116789832A (zh) 2023-09-22
JP2020529863A (ja) 2020-10-15
US11518815B2 (en) 2022-12-06
EP3645742B1 (en) 2026-04-29
EP3645741A2 (en) 2020-05-06
CN116925227A (zh) 2023-10-24
EP3645742A2 (en) 2020-05-06
JP2023065391A (ja) 2023-05-12
CN116731179A (zh) 2023-09-12
JP7323513B2 (ja) 2023-08-08
CN116769035A (zh) 2023-09-19
US11987635B2 (en) 2024-05-21

Similar Documents

Publication Publication Date Title
JP7464764B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
JP7490109B2 (ja) 抗ｐｄ－１抗体とその作製及び使用方法
US20200157224A1 (en) Multi-specific antibodies and methods of making and using thereof
CN101970497A (zh) 抗-EpCAM抗体及其用途
CN116041530A (zh) 多特异性抗体及其制备和使用方法
JP7610680B2 (ja) 抗ｐｄ－ｌ１抗体とその作製及び使用方法
CN110799538A (zh) 抗cd3抗体及其制备和使用方法
US20250376531A9 (en) Anti-4-1bb antibodies and methods of making and using thereof
HK40019010A (en) Multi-specific antibodies and methods of making and using thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240626

Address after: No. 139 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611130

Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region after: China

Address before: 15318 Northeast 95th Street, Redmond, Washington, USA

Applicant before: Seattle Immunization Co.

Country or region before: U.S.A.

Applicant before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd.

Country or region before: China

TA01 Transfer of patent application right